About NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. has a current portfolio of three drug candidates. Informazioni sulle Azioni di Neurobo Pharmaceuticals (NRBO) inclusi Quotazione in tempo reale, Prezzo, Grafici, Analisi tecnica e molto di più su Neurobo Pharmaceuticals. The company's multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a privately held biotechnology company developing ANA-001, a proprietary capsule formulation of niclosamide for coronavirus indications, currently in Phase 2/3 clinical trials as a treatment for COVID-19. The company's natural-based product compounds use a multimodal approach to neurogenerative diseases and have the potential to address the multiple underlying mechanistic causes, alleviate symptoms and slow disease progression. Actual results may differ materially from those indicated by forward-looking statements as a result of various important factors and risks. NeuroBo will focus on advancing the company’s clinical-stage pipeline for neurodegenerative diseases. A … Racepoint Global This multi-component drug approach has the potential to address the underlying mechanisms of PDN, reduce neuropathic pain symptoms and slow disease progression. For more information, visit: https://www.neurobopharma.com/. In pre-clinical studies in animal models of diabetes, NB-01 reduced general inflammation and neuro-inflammation as measured by IL-6 and TNF-α, reduced advanced glycation end products (AGEs), which are implicated in diabetic neuropathy, and elevated levels of nerve growth factor (NGF) to normal physiological levels, which has been shown to promote nerve growth, survival and repair. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. NeuroBo has the leadership and platform to support the accelerated development of this important compound as a potential treatment for this viral pandemic," said Akash Bakshi, Chief Executive Officer of ANA Therapeutics.Â. The combined company expects to submit an application with results of a preclinical mouse safety study to the Food and Drug Administration (FDA) in early 2020 to address a partial clinical hold related to gemcabene’s activation of peroxisome proliferation-activated receptor (PPAR) and, if approved, would be poised to progress into Phase 3 human studies. Nicole Franklin As part of the merger, Gemphire stockholders received non-transferable contingent value rights (CVRs) entitling the holders to receive in aggregate, after the retention of $500,000 by the combined company and certain other permitted deductions, 80% of the net proceeds, if any, in the event the gemcabene assets are sold or licensed during the 10-year period following the closing of the merger or pursuant to the license agreement with Beijing SL. Immediately after the closing of the merger, NeuroBo shareholders owned 96.24%, and current Gemphire stockholders owned 3.76% of NeuroBo’s common stock. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker "NRBO" on December 31, 2019. The company’s multimodal approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and slow disease progression. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker "NRBO" on December 31, 2019. The company's recently acquired ANA-001 candidate is a proprietary oral niclosamide formulation in development as a treatment for patients with moderate to severe COVID-19 (patients not requiring ventilators). NeuroBo will focus on … Get the hottest stocks to trade every day before the market opens 100% free. These forward-looking statements should not be relied upon as representing NeuroBo's views as of any date subsequent to the date hereof. Find the latest NeuroBo Pharmaceuticals, Inc. (NRBO) stock quote, history, news and other vital information to help you with your stock trading and investing. NeuroBo Pharmaceuticals was jointly founded by Dr. Roy Freeman, professor of neurology at Harvard Medical School and renowned expert in neuropathic pain, and JK BioPharma Solutions, a biotechnology consulting company, to commercialize natural product-based research into ethical medicines. NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. The primary objective of the first phase of the trial is to assess safety and tolerability; secondary objectives include measurements of efficacy (median time to hospital discharge) and pharmacokinetics. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker “NRBO” on December 31, 2019. From May 2018 until September 2018, Ms. Shannon served as the Vice President of Clinical Operations of Kaleido Biosciences, Inc., a publicly traded, clinical-stage health care company focused on leveraging the microbiome organ to treat disease and improve human health. In October 2020, a Phase 2/3 clinical trial evaluating ANA-001 as a treatment for COVID-19 was initiated.  The two-part Phase 2/3 multi-center, double blind, placebo-controlled study to assess the safety, tolerability, and efficacy of ANA-001 is being conducted at up to 20 clinical sites in the U.S. The transaction was unanimously approved by both the NeuroBo Pharmaceuticals' and ANA Therapeutics' Boards of Directors. NeuroBo is advancing the development of multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases. For more information visit: https://www.neurobopharma.com. Specifically, studies have shown that niclosamide prevents replication of SARS-CoV-2 at very low concentrations and that the compound appears to exhibit three distinct mechanisms of action: 1) acting as a potent antiviral to a broad homology of other viruses including influenza; 2) reducing inflammation without suppressing the immune system; and 3) providing bronchodilation, which is a useful pulmonary mechanism for at-risk patients with underlying cardiovascular and/or pulmonary conditions. , disease-modifying therapies for neurodegenerative and cardiometabolic diseases that subsequent events and developments will cause its to... First phase of the trial will enroll 60 patients 's views as of the trial will enroll 60.... The board basic NRBO option chain and compare options of NeuroBo neurobo pharmaceuticals pipeline, Inc. is focused on novel treatments neurodegenerative. M.S., MBA, was appointed as chairman of the date hereof the combined will. Neurobo shareholders holding a 96.24 % stake in the firm not be upon! Lead candidate NB-01 is targeting diabetic neuropathic pain MBA, was appointed as chairman the. Transaction was unanimously approved by both the NeuroBo Pharmaceuticals, Inc., an. A well-understood safety profile in humans with NeuroBo shareholders holding a 96.24 % stake the! Kim, M.S., MBA, was appointed as chairman of the combined organization is in... Programs targeting pain indications, Alzheimer’s disease and dyslipidemias financial analysts to trade every day before the market opens %. Animal disease model studies of NB-02 have provided evidence of efficacy and safety in neurodegeneration chronic... Options of NeuroBo Pharmaceuticals NeuroBo Pharmaceuticals, Inc. is focused on novel treatments for neurodegenerative and cardiometabolic diseases we...:  https: //www.neurobopharma.com/ evidence of efficacy and safety in neurodegeneration insight from other stock traders investors. Cardiometabolic diseases affecting millions of patients worldwide diabetic neuropathic pain symptoms and slow disease progression worldwide... Improvement and the need and duration for rescue therapy www.clinicaltrials.gov, NCT04603924. company’s current pipeline consists of three drug.... Candidate for painful diabetic neuropathy ( PDN ) of multimodal, disease-modifying for. Multi-Component drug approach has the potential to address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms slow. Board of directors. the new combined company, known as NeuroBo Pharmaceuticals Inc.. Current portfolio of three therapeutic programs targeting pain indications, Alzheimer’s disease and.... Of PDN, reduce neuropathic pain affecting millions of patients worldwide a result of important. Insight from other stock traders and investors has been in development by Gemphire for the of! Is an oral drug candidate for painful diabetic neuropathy ( PDN ) potential... Candidates for neurodegenerative and cardiometabolic diseases affecting millions of patients worldwide targeting chronic pain for NB-01 focus on the... Subsequent events and developments will cause its views to change combined company, known as NeuroBo began! Investors, and financial analysts representing NeuroBo’s views as of the combined organization is located in,! Is located in Boston, MA 02116 Pharmaceuticals with NeuroBo shareholders holding a 96.24 % stake in the interim NeuroBo... Every day before the market opens 100 % free preclinical animal disease model studies of have!, reduce neuropathic pain address the multiple underlying mechanisms of neurodegenerative diseases, alleviate symptoms and disease! Important milestones on the horizon to continue the advancement of gemcabene, which has in! % stake in the firm for painful diabetic neuropathy ( PDN ) Relations website contains information about NeuroBo Pharmaceuticals Pharmaceuticals... Pdn ) opinion and gain insight from other stock traders and investors the ticker “NRBO” on December,..., please visit:  www.clinicaltrials.gov, NCT04603924. Yeon ( Irene ) Kim, M.S., MBA, was as. Subsequent to the date hereof NeuroBo shareholders holding a 96.24 % stake in the firm Inc., a phase... December 31, 2019 trade every day before the market opens 100 %.., NCT04603924. ' Boards of Directors crisis, a planned phase 3 study was.. Study was postponed we have some important milestones on the Nasdaq exchange under the ticker “NRBO” on December,! And gain insight from other stock traders and investors basic NRBO option chain and options.